MedicalSystem Biotechnology Co., Ltd. Class A

MedicalSystem Biotechnology Co., Ltd. Class A

SSZSE:300439
9.33
CNY
-0.12
(-1.27%)
0.27EPS
38.93P/E
3.93BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.7
2.34
2.2
3.09
7.43
9.23
9.12
6.69
6.02
6.52
4.93
4.52
3.9
4.4
Basic EPS, GAAP
0.41
0.54
0.52
0.52
0.66
0.71
-1.63
0.87
0.48
0.52
0.67
0.67
0.16
0.26
Free Cash Flow per Basic Share
0.11
0.17
0.27
-0.85
-1.39
-0.08
0.69
1.54
0.84
0.69
0.92
-0.06
0.19
- -
Dividend per Share
0.02
0.14
0.01
0.13
0.17
0.34
0.37
0.36
0.24
0.13
0.13
0.14
0.13
0.03
Book Value per Share
2.04
1.22
3.79
4.16
5.45
5.4
3.95
4.79
6.13
6.55
7.09
7.66
7.69
7.92
Tangible Book Value per Share
2.02
1.11
3.6
3
2.45
2.43
3.41
4.27
5.74
6.24
6.75
7.3
7.36
7.63
Basic Weighted Avg Shares
255
255
310
341
348
340
344
344
374
382
383
385
395
382
Sales/Revenue/Turnover
432
598
683
1,055
2,584
3,135
3,133
2,302
2,252
2,489
1,886
1,742
1,539
1,678
Operating Margin (%)
30.52
28.94
25.8
19.97
17.14
14.5
12.03
11.67
13.14
12.57
13.41
14.09
3.99
6.51
Depreciation Expense
20
31
42
68
113
150
161
174
195
192
170
210
173
- -
Net Income, GAAP
104
138
161
177
230
241
-560
299
179
199
257
258
63
101
Effective Tax Rate (%)
20.03
17.97
16.74
16.79
25.67
26.95
- -
15.41
12.87
8.11
12.24
6.97
- -
0.22
Profit Margin (%)
23.96
23.03
23.61
16.82
8.89
7.69
-17.87
13.01
7.97
7.98
13.6
14.81
4.11
5.99
Working Capital
157
237
1,015
532
618
221
99
161
949
1,090
1,200
1,157
1,269
1,401
LT Debt
- -
- -
- -
104
18
120
243
130
71
34
24
37
28
20
Total Equity
308
415
1,287
1,519
2,287
2,270
1,416
1,687
2,391
2,519
2,707
2,933
2,948
3,036
Return on Invested Capital (%)
29.83
29.62
16.18
10.61
9.28
6.73
- -
5.32
7.06
7.55
8.98
8.82
- -
3.05
Return on Capital (%)
32.74
31.78
18.3
10.8
8.17
8.05
- -
12.62
7.02
7.21
9.31
8.79
- -
3.34
Return on Common Equity (%)
40.7
38.25
18.95
12.98
13.75
12.82
-34.62
19.93
9
8.17
9.82
9.12
2.14
3.35

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
12
72
72
LT Borrowings
- -
- -
- -
LT Finance Leases
26
23
20
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
384
384
384
Market Capitalization
3,709
3,086
3,934

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,846
1,983
2,019
Cash, Cash Equivalents & STI
827
1,042
1,012
Accounts Receivable, Net
609
614
650
Inventories
251
228
268
Total Current Liabilities
534
640
618
Payables & Accruals
- -
- -
- -
ST Debt
12
72
72
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.27%
12.68%
0.48%
Free Cash Flow
-187.3%
-111.92%
-430.93%
Net Income, GAAP
-51.64%
-15.03%
-75.5%
Sales/Revenue/Turnover
15.9%
-7.03%
-11.67%
Total Cash Common Dividend
174.31%
-13.79%
-0.92%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
482
468
458
336
1,742
2025
374
362
- -
403
1,539
2026
376
452
446
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
0.26
0.12
0.09
0.67
2025
0.08
0.07
- -
0.01
0.16
2026
0.09
0.07
0.09
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.14
- -
- -
0.14
2025
- -
0.08
- -
- -
0.13
2026
- -
0.02
0.01
- -
- -

Company Description

CEO
Ji Hua Zou
Full Time Employees
1,936
Sector
Health technology
Industry
Medical specialties
Address
No. 299, Qiming South Road Ningbo ZH China 315104
IPO Date
Apr 13, 2015
Business
Medicalsystem Biotechnology Co., Ltd. is a China-based company primarily engaged in the research, development, manufacturing, and sale of biochemical reagents, medical laboratory systems, and diagnostic instruments. Its main product lines include biochemical reagents, immunodiagnostic reagents, molecular diagnostics products, clinical automation laboratory systems, and laboratory information management systems. The company offers a comprehensive range of medical diagnostic solutions including clinical chemistry, immunoassay, molecular diagnostics, and in vitro diagnostic (IVD) instruments, serving hospitals, clinical laboratories, and medical institutions across China and internationally. Founded in 2008 and headquartered in Ningbo, Zhejiang Province, Medicalsystem Biotechnology focuses on advancing medical technology integration with a strong emphasis on innovative diagnostic assays and automated testing platforms. In the last two years, Medicalsystem Biotechnology has made strategic advancements, including launching new molecular diagnostic products that broaden its capabilities in infectious disease testing and genetic screening. The company has also increased its global reach through strengthened partnerships with international distributors and expanded its service network overseas, especially in Southeast Asia. Notably, Medicalsystem Biotechnology completed significant investments in upgrading its R&D facilities and production lines to enhance manufacturing capacity and product quality. Additionally, the company has been actively pursuing certifications and regulatory approvals to comply with key markets' standards, which has facilitated recent business expansions and collaborations within the biotech and healthcare sectors. Medicalsystem Biotechnology operates primarily in the biotech and medical diagnostics industry, targeting clinical laboratories, hospitals, and healthcare providers seeking advanced diagnostic reagents and instruments for disease detection and patient health monitoring. Its comprehensive product portfolio and service offerings enable it to cater to a broad spectrum of diagnostic needs ranging from routine clinical testing to cutting-edge molecular diagnostics. The company is headquartered in Ningbo, Zhejiang Province, China, and continues to expand its influence both domestically and internationally through strategic alliances and continuous product innovation. It remains focused on developing integrated diagnostic solutions that enhance clinical decision-making and improve patient outcomes in the healthcare ecosystem.